| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000019908 |
| Receipt No. | R000022993 |
| Official scientific title of the study | Preliminary study of [11C]methionine PET/CT in the diagnosis of IgG4 related disease |
| Date of disclosure of the study information | 2016/01/01 |
| Last modified on | 2017/08/08 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Preliminary study of [11C]methionine PET/CT in the diagnosis of IgG4 related disease
|
|
| Title of the study (Brief title) | Preliminary study of [11C]methionine PET/CT in the diagnosis of IgG4 related disease | |
| Region |
|
|
| Condition | |||
| Condition | IgG4 related disease | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | 1) To evaluate the ability of [11C] methionine PET/CT in the diagnosis of IgG4 related disease
2) To evaluate the ability of [11C] methionine PET/CT in the prediction of prognosis and therapeutic effect for IgG4 related disease |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | 1) Validation of [11C] methionine PET/CT images from the viewpoint of nuclear medicine physicians
2) Differences between [11C] methionine and [18F] FDG 3) Differences in the uptake between before and after treatment 4) Relevance to the PET uptake with clinical findings in the cases of treatment failure |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Diagnosis | ||
| Type of intervention |
|
||
| Interventions/Control_1 | [11C]methionine PET/CT, [18F]FDG PET/CT | ||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) 20 y/o or older
2) Diagnosed as definite, probable or possible group of IgG4-related group by the Comprehensive Diagnostic Criteria for IgG4-Related disease 3) Before the treatment for IgG4-related disease by the administration of steroid 4) Written informed consent was acquired |
|||
| Key exclusion criteria | 1) Pregnancy or possibility of pregnancy
2) Image acquisition by PET/CT is impossible due to the pain or poor performance status 3) Considered inadequate to attend this study by the researcher |
|||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Tomohiko Yamane |
| Organization | Saitama Medical University International Medical Center |
| Division name | Nuclear Medicine |
| Address | Yamane 1397-1, Hidaka |
| TEL | 042-984-4111 |
| yamane@mail.ne.jp | |
| Public contact | |
| Name of contact person | Tomohiko Yamane |
| Organization | Saitama Medical University International Medical Center |
| Division name | Nuclear Medicine |
| Address | Yamane 1397-1, Hidaka |
| TEL | 042-984-4111 |
| Homepage URL | |
| yamane@mail.ne.jp | |
| Sponsor | |
| Institute | Saitama Medical University International Medical Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Self funding |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Saitama Medical University Hospital |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022993 |